Nuclear Science and Engineering Center, Japan Atomic Energy Agency, Tokai, 319-1195, Japan.
Faculty of Health Sciences, Hokkaido University, Sapporo, 060-0812, Japan.
Sci Rep. 2024 Jul 19;14(1):16696. doi: 10.1038/s41598-024-67041-6.
Boron neutron capture therapy (BNCT) is a unique radiotherapy of selectively eradicating tumor cells using boron compounds (e.g., 4-borono-L-phenylalanine [BPA]) that are heterogeneously taken up at the cellular level. Such heterogenicity potentially reduces the curative efficiency. However, the effects of temporospatial heterogenicity on cell killing remain unclear. With the technical combination of radiation track detector and biophysical simulations, this study revealed the cell cycle-dependent heterogenicity of BPA uptake and subsequent biological effects of BNCT on HeLa cells expressing fluorescent ubiquitination-based cell cycle indicators, as well as the modification effects of polyvinyl alcohol (PVA). The results showed that the BPA concentration in the S/G/M phase was higher than that in the G/S phase and that PVA enhances the biological effects both by improving the uptake and by canceling the heterogenicity. These findings might contribute to a maximization of therapeutic efficacy when BNCT is combined with PVA and/or cell cycle-specific anticancer agents.
硼中子俘获治疗(BNCT)是一种独特的放射疗法,利用硼化合物(如 4-硼代-L-苯丙氨酸 [BPA])选择性地消灭肿瘤细胞,这些化合物在细胞水平上不均匀地摄取。这种不均匀性可能会降低治疗效果。然而,时空不均匀性对细胞杀伤的影响尚不清楚。本研究通过辐射轨迹探测器和生物物理模拟的技术组合,揭示了表达荧光泛素化细胞周期指示剂的 HeLa 细胞中 BPA 摄取的细胞周期依赖性不均匀性以及随后 BNCT 的生物学效应,以及聚乙烯醇(PVA)的修饰作用。结果表明,S/G/M 期的 BPA 浓度高于 G1/S 期,并且 PVA 通过提高摄取和消除不均匀性来增强生物学效应。这些发现可能有助于在 BNCT 与 PVA 和/或细胞周期特异性抗癌药物联合使用时最大限度地提高治疗效果。